Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-209-6400
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees112
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Deciphera Pharmaceuticals (NASDAQ:DCPH) Frequently Asked Questions
What is Deciphera Pharmaceuticals' stock symbol?
Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."
How were Deciphera Pharmaceuticals' earnings last quarter?
Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) released its quarterly earnings results on Friday, August, 2nd. The company reported ($0.56) EPS for the quarter, topping analysts' consensus estimates of ($1.12) by $0.56. The company had revenue of $25 million for the quarter, compared to the consensus estimate of $20 million. View Deciphera Pharmaceuticals' Earnings History.
When is Deciphera Pharmaceuticals' next earnings date?
What price target have analysts set for DCPH?
10 analysts have issued 12-month price objectives for Deciphera Pharmaceuticals' stock. Their predictions range from $29.00 to $66.00. On average, they anticipate Deciphera Pharmaceuticals' share price to reach $51.30 in the next year. This suggests a possible upside of 49.9% from the stock's current price. View Analyst Price Targets for Deciphera Pharmaceuticals.
What is the consensus analysts' recommendation for Deciphera Pharmaceuticals?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Deciphera Pharmaceuticals.
What are Wall Street analysts saying about Deciphera Pharmaceuticals stock?
Here are some recent quotes from research analysts about Deciphera Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Deciphera Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib which are in clinical stage. Deciphera Pharmaceuticals, LLC is based in WALTHAM, United States. " (10/4/2019)
- 2. Cantor Fitzgerald analysts commented, "We are Overweight on DCPH with a 12-month price target of $53 based on lead asset DCC-2618 (in 4L GIST). Compelling safety and clinical activity data were presented at ASCO ‘18, which we view positively when compared to SOC sunitinib in earlier 2L patients. We believe the recent data de-risks the P3 program for 4L pts, reads on the broad potential in GIST & other malignancies, and reinforces our conviction in the platform/clinical strategy. In addition, emerging ‘2618 data in 2L/3L pts suggest superiority to SOC in terms of response rate & durability, a clinical profile that could drive ~$2.7B in peak sales." (12/20/2018)
Has Deciphera Pharmaceuticals been receiving favorable news coverage?
News stories about DCPH stock have been trending somewhat positive on Saturday, according to InfoTrie. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Deciphera Pharmaceuticals earned a daily sentiment score of 0.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Deciphera Pharmaceuticals.
Are investors shorting Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 3,020,000 shares, an increase of 39.2% from the August 30th total of 2,170,000 shares. Based on an average daily trading volume, of 781,700 shares, the days-to-cover ratio is presently 3.9 days. Currently, 10.9% of the shares of the stock are sold short. View Deciphera Pharmaceuticals' Current Options Chain.
Who are some of Deciphera Pharmaceuticals' key competitors?
Some companies that are related to Deciphera Pharmaceuticals include Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Beigene (BGNE), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Horizon Therapeutics (HZNP), Reata Pharmaceuticals (RETA), The Medicines (MDCO), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), United Therapeutics (UTHR), FibroGen (FGEN) and Mirati Therapeutics (MRTX).
What other stocks do shareholders of Deciphera Pharmaceuticals own?
Who are Deciphera Pharmaceuticals' key executives?
Deciphera Pharmaceuticals' management team includes the folowing people:
- Dr. Daniel L. Flynn, Exec. VP, Chief Scientific Officer & Founder (Age 64)
- Mr. Christopher J. Morl, Chief Bus. Officer (Age 60)
- Countess Steven L. Hoerter, Pres, CEO & Director (Age 48)
- Mr. Thomas Patrick Kelly J.D., Exec. VP, CFO & Treasurer (Age 48)
- Dr. Stephen B. Ruddy Ph.D., Chief Technical Officer (Age 55)
When did Deciphera Pharmaceuticals IPO?
(DCPH) raised $101 million in an IPO on Thursday, September 28th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.
Who are Deciphera Pharmaceuticals' major shareholders?
Deciphera Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Zurcher Kantonalbank Zurich Cantonalbank (0.00%). Company insiders that own Deciphera Pharmaceuticals stock include Daniel C Martin, Daniel Lee Flynn, James Arthur Bristol, Michael Douglas Taylor, New Leaf Venture Management Ii and Thomas Patrick Kelly. View Institutional Ownership Trends for Deciphera Pharmaceuticals.
Which institutional investors are buying Deciphera Pharmaceuticals stock?
How do I buy shares of Deciphera Pharmaceuticals?
Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Deciphera Pharmaceuticals' stock price today?
One share of DCPH stock can currently be purchased for approximately $34.23.
How big of a company is Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals has a market capitalization of $1.73 billion. The company earns $-99,850,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis. Deciphera Pharmaceuticals employs 112 workers across the globe.View Additional Information About Deciphera Pharmaceuticals.
What is Deciphera Pharmaceuticals' official website?
How can I contact Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals' mailing address is 500 Totten Pond Road, Waltham MA, 02451. The company can be reached via phone at 781-209-6400 or via email at [email protected]
MarketBeat Community Rating for Deciphera Pharmaceuticals (NASDAQ DCPH)
MarketBeat's community ratings are surveys of what our community members think about Deciphera Pharmaceuticals and other stocks. Vote "Outperform" if you believe DCPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DCPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
